Amedex Biotherapeutics moves listing to Nasdaq Capital Market
Amedex Biotherapeutics (LABT.O) shifted its stock listing to the Nasdaq Capital Market on April 23, 2026, following a $7.5 million private placement of Series C Convertible Preferred Stock. The listing simplifies its capital structure, with earlier preferred stock and convertible notes converted into common stock. Shar